Inicio/Acciones/NLSP

NLSP

USD

NLS Pharmaceutics Ltd. Ordinary Shares

$0.762-0.008 (-1.039%)

Precio en Tiempo Real

Healthcare

Biotecnología

Suiza

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado

Fundamentos de la Empresa

Estadísticas de Negociación

Métricas de Mercado

Apertura

$0.770

Máximo

$0.830

Mínimo

$0.760

Volumen

0.00M

Fundamentos de la Empresa

Capitalización de Mercado

4.0M

Industria

Biotecnología

País

Switzerland

Estadísticas de Negociación

Volumen Promedio

0.07M

Bolsa

NCM

Moneda

USD

Rango de 52 Semanas

Mínimo $0.76Actual $0.762Máximo $43.4

Noticias Relacionadas

30 oct 2025 · 20:15

PR Newswire

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

NewcelX Ltd. ("NewcelX" or the "Company") completed the previously announced merger transaction, pursuant to that certain Agreement of Merger and...

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

30 oct 2025 · 11:00

PR Newswire

NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and...

NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

29 oct 2025 · 10:00

PR Newswire

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

29 oct 2025 · 07:53

PR Newswire

NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem") today announced that,...

NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

27 oct 2025 · 11:00

PR Newswire

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and...

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

PR Newswire

23 oct 2025 · 10:01

NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central...